ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.
about
Matrix-M™ adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigenImmune response to vaccine adjuvants during the first year of lifeSynthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial VirusSaponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formationEvaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunizationPulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing.New adjuvanted vaccines in pregnancy: what is known about their safety?Identification of Molecular Signatures from Different Vaccine Adjuvants in Chicken by Integrative Analysis of Microarray Data.Design and synthesis of potent Quillaja saponin vaccine adjuvantsCoadministration of polyinosinic:polycytidylic acid and immunostimulatory complexes modifies antigen processing in dendritic cell subsets and enhances HIV gag-specific T cell immunity.ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.Long-term antibody and immune memory response induced by pulmonary delivery of the influenza Iscomatrix vaccineISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway.Meta-Analysis on Randomized Controlled Trials of Vaccines with QS-21 or ISCOMATRIX Adjuvant: Safety and Tolerability.Synthesis and preclinical evaluation of QS-21 variants leading to simplified vaccine adjuvants and mechanistic probesStrategies for intranasal delivery of vaccinesThe role of ISCOMATRIX bilayer composition to induce a cell mediated immunity and protection against leishmaniasis in BALB/c mice.Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer.Reduced MyD88 dependency of ISCOMATRIX™ adjuvant in a DNA prime-protein boost HIV vaccine.Dendritic cell-based cancer vaccination: quo vadis?Vaccines for the future: learning from human immunologyDevelopment of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.The CD8⁺ T Cell-Mediated Immunity Induced by HPV-E6 Uploaded in Engineered Exosomes Is Improved by ISCOMATRIXTM Adjuvant.Archaeal lipid mucosal vaccine adjuvant and delivery system.The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease.Combination of adjuvants: the future of vaccine design.Enhancing Immunogenicity of Cancer Vaccines: QS-21 as an Immune Adjuvant.Carbohydrate-based vaccine adjuvants - discovery and development.Trans-sialidase overcomes many antigens to be used as a vaccine candidate against Trypanosoma cruzi.Overview of Vaccine Adjuvants: Introduction, History, and Current Status.An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma.Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria.Enhanced immunization via dissolving microneedle array-based delivery system incorporating subunit vaccine and saponin adjuvant.Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.Intradermal immunization by Ebola virus GP subunit vaccines using microneedle patches protects mice against lethal EBOV challengeQuillaja brasiliensis saponin-based nanoparticulate adjuvants are capable of triggering early immune responses
P2860
Q21134130-D871ADD0-B9AC-444D-B14A-52C9C6728BA9Q27016633-28684B1F-7EE6-41CC-B81B-918CE034FBACQ28067143-BBCE174F-CD4A-4088-BAD3-753580A28807Q28393754-2B4F6C7E-473F-4944-A500-53B99DDA7F3BQ30227975-2220A7BA-2494-4871-8B85-FF9AEC5840FBQ30373902-F409A37D-B6CF-4D6B-A894-7218060EB9DBQ30396657-136FABD1-1422-4EC1-8D63-1F719751CC2FQ31054454-C7AE58D7-66CB-45BC-8CA4-F8AFD44EFD07Q33645835-97DA81CA-F3CB-4B12-ACE3-E5ADF3316393Q33909362-BA0BC501-56F3-48FC-844C-55C3E46DEB94Q34848159-D75AF111-0E80-4ACF-B42B-474920206C40Q35666175-FA627188-1A14-4833-9A57-FC087B865EEEQ36001701-86E2E42A-71CC-4B5B-AD15-E9F1FCF694E9Q36009558-5835958C-824D-40C1-A57A-5D63490BF0F8Q36216866-88E83EC3-CB43-4D7C-BA0F-D2DC2CF4C75DQ36514771-99B6AB97-E73B-4582-9804-05E09F3E2618Q36758235-790DA0D9-9025-4625-AFB1-2D8C1CDBAD3CQ36856279-AE3BDBE8-0F95-463A-9655-778B7D4AD5BCQ36977750-989EA8BE-CFDD-4A10-9393-2C4E5EC7F280Q37259624-17CED3B8-CA04-4605-9C19-965A03716531Q37274689-CFB802FB-460B-4659-85E2-3A5A20BBD509Q37452772-B98A0AC6-C444-4440-964C-FEAAC19C0F43Q37539231-44B583C7-8CFF-4520-8F93-39946A05CD8CQ37724863-D1623174-857B-427C-992C-2081891F8E88Q37903445-BA8A6653-38B5-4A70-B365-9FDC24D65D86Q38124060-DF506CF7-A1E9-41E3-A0DD-CA23BEA99A82Q38282887-B799EF0D-F33A-4B88-92E1-B3E62C111474Q38587300-C2D27EF1-78ED-4CBE-890A-86F2F4B2478BQ38735876-C3531351-EA59-4218-931F-2080737D3257Q38813523-5C0AA7EC-E527-4583-AD23-AF6AF60EE484Q39703281-FB1D4382-2D30-4BFB-9294-EE81499B0B37Q40094062-B7CCD5F3-2A91-4960-A59D-A5B9D7C62474Q40970607-9A8CB68B-457D-4ECE-8A02-AC84944AD2BDQ52725104-7AEFD4AF-2681-484D-B07E-46A4004702EFQ56945995-63A13E7F-EB13-4420-A0F5-943B51FD9E59Q58751640-2973016B-6A25-4B7D-97B9-073F23582524
P2860
ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.
@en
type
label
ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.
@en
prefLabel
ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.
@en
P2093
P2860
P356
P1476
ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.
@en
P2093
Charmaine Gittleson
Debbie Drane
Eugene Maraskovsky
Jeff Boyle
P2860
P304
P356
10.1586/14760584.6.5.761
P577
2007-10-01T00:00:00Z